Ontology highlight
ABSTRACT:
SUBMITTER: Atallah E
PROVIDER: S-EPMC5176249 | biostudies-literature | 2009 May
REPOSITORIES: biostudies-literature
Atallah Ehab E Verstovsek Srdan S
Expert review of anticancer therapy 20090501 5
The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: almost all patients with polycythemia vera harbor the mutation and about 50% of patients with essential thrombocythemia and primary myelofibrosis have the mutation, making the development of JAK2 tyrosi ...[more]